Paris - Delayed Quote EUR

GeNeuro SA (GNRO.PA)

0.0712

+0.0004

+(0.56%)

As of 3:06:04 PM GMT+2. Market Open.

GeNeuro SA Announces Definitive Debt-Restructuring Moratorium

GENEVA, May 27, 2025--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court of First Instance has, in a May 26, 2025, judgment, granted GeNeuro SA a four-month definitive debt-restructuring moratorium, under the continued supervision of the court-appointed commissary.

Business Wire 9 days ago

GNRO.PA
+0.56%
GeNeuro SA Announces the Postponement of the Publication of the Company's 2024 Annual Results

GENEVA, Switzerland, May 12, 2025--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces the postponement of the publication of its December 31, 2024 annual results and annual financial report in order to be able to take into account the financial impacts of the restructuring targeted by the Company as part of the granted debt-restructuring moratorium procedure. The Company wi

Business Wire 24 days ago

GNRO.PA
+0.56%
GeNeuro SA Announces Renewal of Provisional Debt-Restructuring Moratorium

GENEVA, January 28, 2025--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court of First Instance has renewed the provisional debt-restructuring moratorium granted to the Company in September 2024. The moratorium has been extended for an additional four months, until May 27, 2025, under the continued supervision of a court-appointed commissary.

Business Wire 4 months ago

GNRO.PA
+0.56%
New Data Supporting a New Precision Medicine Approach for ALS Patients With GeNeuro’s GNK-301 Presented at the 35th International Symposium on ALS/MND

GENEVA, December 06, 2024--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and autoimmune diseases, such as amyotrophic lateral sclerosis (ALS), today announced that groundbreaking findings on a potential precision medicine strategy for ALS with GeNeuro’s GNK-301 were presented at the 35th International Symposium on ALS/MND, taking place in Montreal, Canada, from December 6-

Business Wire 5 months ago

GNRO.PA
+0.56%
GeNeuro SA Obtains the Opening of Debt-Restructuring Proceedings

GENEVA, September 30, 2024--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court of First Instance has approved its application for a debt-restructuring moratorium dated July 15, 2024, aimed at restructuring its debts and finding solutions for the continuity of its activities in the interests of all stakeholders.

Business Wire 8 months ago

GNRO.PA
+0.56%
GeNeuro: New Data Presented at the ECTRIMS 2025 Congress in Copenhagen Shows That Temelimab Rescues the Neurodegenerative Effects of HERV-W in an MS Model

GENEVA, September 19, 2024--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that new findings on the anti-neurodegenerative effect of Temelimab in an MS model were presented as a poster at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 Congress in Copenhagen, Den

Business Wire 8 months ago

GNRO.PA
+0.56%
GeNeuro Announces That It Submits a Request for a Debt Moratorium to the Geneva Court of First Instance

GENEVA, July 15, 2024--Regulatory News: GeNeuro (Euronext Paris : CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or COVID-Long), announces that it will submit today to the Geneva Court of First Instance a request for a debt moratorium to restructure its debts and find solutions for the

Business Wire 10 months ago

GNRO.PA
+0.56%
GeNeuro SA: End of the Liquidity Contract With GILBERT DUPONT

GENEVA, July 10, 2024--Regulatory News: GeNeuro SA (Paris:GNRO) and GILBERT DUPONT have terminated the liquidity contract entered into on March 6, 2021.

Business Wire 10 months ago

GNRO.PA
+0.56%
Geneuro SA: Half-Yearly Report on the Liquidity Contract with Gilbert Dupont

GENEVA, July 03, 2024--Regulatory News: Pursuant to the liquidity contract entrusted by GENEURO SA (Paris:GNRO) to Gilbert Dupont, as of 28 June 2024, the following assets appeared on the liquidity account:

Business Wire 10 months ago

GNRO.PA
+0.56%
GeNeuro Announces Results of the GNC-501 Study in Post-Covid-19 Syndrome

GENEVA, Switzerland, June 28, 2024--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 – GNRO):

Business Wire 11 months ago

GNRO.PA
+0.56%
GeNeuro Announces Approval of all Resolutions Proposed at 2024 Annual General Meeting

GENEVA, Switzerland, June 14, 2024--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today announced that its shareholders have approved all resolutions proposed at its Annual General Meeting (AGM) of 12 June 2024. These included amon

Business Wire 11 months ago

GNRO.PA
+0.56%

Performance Overview

Return	GNRO.PA	CAC 40 (^FCHI)
YTD	-8.95%	+5.81%
1-Year	-96.76%	-2.87%
3-Year	-97.67%	+19.25%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

GeNeuro SA (GNRO.PA)

GeNeuro SA Announces Definitive Debt-Restructuring Moratorium

GeNeuro SA Announces the Postponement of the Publication of the Company's 2024 Annual Results

GeNeuro SA Announces Renewal of Provisional Debt-Restructuring Moratorium

New Data Supporting a New Precision Medicine Approach for ALS Patients With GeNeuro’s GNK-301 Presented at the 35th International Symposium on ALS/MND

GeNeuro SA Obtains the Opening of Debt-Restructuring Proceedings

GeNeuro: New Data Presented at the ECTRIMS 2025 Congress in Copenhagen Shows That Temelimab Rescues the Neurodegenerative Effects of HERV-W in an MS Model

GeNeuro Announces That It Submits a Request for a Debt Moratorium to the Geneva Court of First Instance

GeNeuro SA: End of the Liquidity Contract With GILBERT DUPONT

Geneuro SA: Half-Yearly Report on the Liquidity Contract with Gilbert Dupont

GeNeuro Announces Results of the GNC-501 Study in Post-Covid-19 Syndrome

GeNeuro Announces Approval of all Resolutions Proposed at 2024 Annual General Meeting

Performance Overview